Monday, November 18, 2019

FDA Approves Pfizer's ABRILADA, Fifth Biosimilar To Humira

Pfizer Inc.'s ( PFE) ABRILADA, a biosimilar to Humira, has received FDA approval for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

from RTT - Biotech https://ift.tt/2CSsZ2P
via IFTTT

No comments:

Post a Comment